Intuitive Surgical (Nasdaq: ISRG) released unaudited preliminary financial results for Q4 and full-year 2025 on Jan 14, 2026, and is slated to discuss the 2025 financial results in more detail during a conference call today, Jan 22, 2026. Results show robust growth in procedures and revenue.
Procedure Volume Growth
Worldwide da Vinci and Ion procedures grew 18% in Q4 2025 versus Q4 2024. Da Vinci procedures rose 17%. Ion procedures increased 44%. Full-year combined procedures climbed 19%, with da Vinci up 18% and Ion up 51%. Da Vinci systems saw 3,153,000 procedures in 2025, an 18% rise from 2,683,000 in 2024. U.S. general surgery procedures grew 18%. Procedures outside the U.S. rose 23%. Intuitive expects 13%-15% da Vinci procedure growth in 2026.
System Placements
The company placed 532 da Vinci systems in Q4 2025, up from 493 in Q4 2024. Of these, 303 were da Vinci 5 systems, versus 174 prior year. Full-year placements reached 1,721 systems, including 870 da Vinci 5, compared to 1,526 total in 2024. Ion placements fell to 42 in Q4 from 69, and 195 for the year from 271. Operating leases included 250 da Vinci systems in Q4, with 150 usage-based.
Revenue Breakdown
Preliminary Q4 revenue hit $2.87 billion, up 19% from $2.41 billion. Instruments and accessories revenue grew 17% to $1.66 billion. Systems revenue reached $786 million, up from $655 million. Full-year revenue was $10.06 billion, a 21% increase from $8.35 billion. Instruments and accessories rose 19% to $6.02 billion. Systems revenue increased to $2.47 billion from $1.97 billion. Average da Vinci utilization rose 4%.
Other Highlights
Q4 expenses included a $70 million Intuitive Foundation contribution, up from $45 million. Results remain preliminary pending final audit. CEO Dave Rosa noted strong adoption of surgical platforms and over 3.1 million da Vinci procedures.
About
Intuitive Surgical, based in Sunnyvale, California, leads in minimally invasive care and pioneered robotic-assisted surgery. Its technologies include da Vinci surgical systems and the Ion endoluminal system, combining advanced tools, learning programs, and services to optimize physician care delivery and patient outcomes. The company envisions less invasive care that detects diseases early for faster recovery.